Combination of a PI3K-and a PARP-inhibitor to treat high-grade serous ovarian or triple-negative breast cancer

被引：1
|
作者：
Wulf, Gerburg M. [1 ]
Juvekar, Ashish [1 ]
Lyssiotis, Costas A. [2 ]
Hu, Hai [1 ]
Yadegarynia, Sina [1 ]
Liu, Hui [1 ]
Kim, Baek [3 ]
Winter, Eric [4 ]
Scully, Ralph [1 ]
Asara, John [1 ]
Cantley, Lewis C. [2 ]
Matulonis, Ursula [4 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Weill Cornell Med Sch, New York, NY USA
[3] Emory Sch Med, Atlanta, GA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT338
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT338
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
    Prvanovic, Mirjana
    Nedeljkovic, Milica
    Tanic, Nasta
    Tomic, Tijana
    Terzic, Tanja
    Milovanovic, Zorka
    Maksimovic, Zlatko
    Tanic, Nikola
    LIFE-BASEL, 2021, 11 (11):
  • [32] Pamiparib dose escalation in Chinese patients with non-mucinous high-grade ovarian cancer or advanced triple-negative breast cancer
    Xu, Binghe
    Yin, Yongmei
    Dong, Mei
    Song, Yan
    Li, Wei
    Huang, Xiang
    Wang, Tongshan
    He, Jing
    Mu, Xiyan
    Li, Li
    Mu, Song
    Zhang, Wa
    Li, Miao
    CANCER MEDICINE, 2021, 10 (01): : 109 - 118
  • [33] SPONTANEOUS PATHOLOGICAL COMPLETE REGRESSION OF HIGH-GRADE TRIPLE-NEGATIVE BREAST CANCER WITH AXILLARY METASTASIS
    Cserni, Gabor
    Serfozo, Orsolya
    Ambrozay, Eva
    Marko, Laszlo
    Krenacs, Laszlo
    POLISH JOURNAL OF PATHOLOGY, 2019, 70 (02) : 139 - 143
  • [34] EXPLORATION OF RESISTANCE OF PARP INHIBITOR THERAPY IN HIGH-GRADE SEROUS OVARIAN CANCER PATIENT-DERIVED XENOGRAFTS.
    Ye, L.
    Topp, M.
    Boehm, E.
    Hadley, A.
    Cook, M.
    Heong, V.
    Pyman, J.
    McNally, O.
    Ananda, S.
    Harrell, M.
    Alsop, K.
    Bowtell, D. D.
    Johnson, N.
    Kaufmann, S. H.
    Swisher, E. M.
    Wakefield, M.
    Scott, C. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 407 - 408
  • [35] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple-negative breast cancer
    Solzak, Jeffrey P.
    Atale, Rutuja
    Hancock, Brad
    Radovich, Milan
    CANCER RESEARCH, 2015, 75
  • [36] PI3K Inhibitor Increased Radiosensitizing Effect of PARP Inhibitor in BRCA-Proficient Triple Negative Breast Cancer Cells
    Kim, I. A.
    Jang, N. Y.
    Kim, D. H.
    Cho, B. J.
    Choi, E. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E533 - E534
  • [37] Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor
    Song, Dandan
    He, Huan
    Sinha, Indranil
    Hases, Linnea
    Yan, Feifei
    Archer, Amena
    Haldosen, Lars-Arne
    Zhao, Chunyan
    Williams, Cecilia
    CANCER LETTERS, 2021, 506 : 23 - 34
  • [38] Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells
    Eskiler, Gamze Guney
    Ozturk, Melek
    CELLULAR SIGNALLING, 2022, 91
  • [39] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC).
    Zhou, Yinghui
    Wang, Sarah
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing Yu
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 32 - 33
  • [40] FDG PET early metabolic response to the PARP inhibitor olaparib (AZD2281) in BRCA-deficient or recurrent high-grade ovarian carcinoma and BRCA-deficient or triple-negative breast cancer
    Benard, Francois
    Roy, Felix-Nicolas
    Wilson, Don
    Martin, Montgomery
    Hoskins, Paul
    Swenerton, Ken
    Tchakov, Ilian
    Watkins, Claire
    Tracy, Michael
    Gelmon, Karen
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
12345